Angiogenesis inhibitors, such as TNP-470 and the nontoxic HPMA copolymer-TNP-470 (caplostatin), are emerging as a class of anticancer drugs. We report that TNP-470 and caplostatin inhibit vascular hyperpermeability of tumor blood vessels as well as that induced in mouse skin by different mediators. Treatment with TNP-470 or angiostatin for 3 days was sufficient to reduce permeability of tumor blood vessels, delayed-type hypersensitivity, and pulmonary edema induced by IL-2. TNP-470 also inhibited VPF/VEGF-induced phosphorylation of VEGFR-2, calcium influx, and RhoA activation in endothelial cells. These results identify an activity of TNP-470, that of inhibiting vessel hyperpermeability. This activity likely contributes to TNP-470's antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation.
ogenesis (Ingber et al., 1990) and to inhibit tumor growth in several preclinical studies (Kragh et al., 1999) as well as in clinical trials (Milkowski and Weiss, 1999) . TNP-470's clinical utility was limited by neurotoxicity, a complication that has recently been overcome by conjugating it to a water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer (Satchi-Fainaro et al., 2004) . At present, the only known molecular target of TNP-470 is methionine aminopeptidase-2 (MetAP2) (Griffith et al., 1997) , a cytoplasmic metalloenzyme responsible for removing the N-terminal methionine from nascent proteins. However, it is unclear how inhibition of this ubiquitously expressed protein affects TNP-470's action on EC proliferation (Ingber et al., 1990) . To date, there is no evidence for TNP-470 binding an extracellular receptor.
TNP-470's effect on tumor growth has been thought to result mainly from its effects on EC proliferation (Abe et al., 1994) . However, we demonstrate here that both TNP-470 and its nontoxic high-molecular weight HPMA copolymer conjugate, caplostatin, strikingly inhibit the vascular permeability-inducing effects of VPF/VEGF as well as that of platelet-activating factor (PAF) and histamine. TNP-470 inhibited extravasation of plasma proteins across microvascular endothelium in response to VPF/ VEGF and other mediators in vivo as well as signaling pathways mediated through VEGFR-2, Ca 2+ influx, and RhoA activation on cultured endothelium. In addition, we show that TNP-470 inhibits the vascular hyperpermeability found in tumors and in delayed-type hypersensitivity (DTH) reactions, as well as in the pulmonary edema induced by interleukin-2 (IL-2). We also show that angiostatin, another angiogenesis inhibitor (O'Reilly et al., 1994) , inhibits vascular permeability. Taken together, we demonstrate a mechanism by which TNP-470 and at least one other inhibitor antagonizes angiogenesis. Figure 1 . TNP-470 prevents vascular permeability in mouse skin capillaries Vessel permeability was assessed by the Miles assay. Mice were pretreated systemically with saline, methyl cellulose, Herceptin, thalidomide, angio-TNP-470, caplostatin, and angiostatin reduce statin, TNP-470, or caplostatin for 3-5 days and were then anesthetized and microvessel permeability administered Evans blue i.v. (10 min) followed by intradermal injection of The Miles assay was used to determine whether TNP-470, PBS (50 l) and VPF/VEGF (50 ng in 50 l) for 20 min.
Results
caplostatin, or angiostatin affected vascular permeability, a A: Diminished dye is observed in mice treated with free or conjugated TNP-470 and angiostatin compared to treatment with thalidomide, Herceptin, prominent early feature of pathological angiogenesis (Figure 1 ). or methyl cellulose and saline.
Evans blue dye was injected i.v., and immediately thereafter B: Skin was excised, and extracted dye contents were quantified by measseveral vascular permeability-inducing agents (VPF/VEGF, PAF, uring at 620 nm. Data are expressed as mean ± SE. histamine) were injected into the shaved flank skin of SCID C: Quantification of dye extracted from PBS (black columns)-, VEGF (gray mice. Evans blue dye binds to plasma proteins and therefore columns)-, PAF (white columns)-, and histamine (striped columns)-induced permeability sites following treatments with TNP-470, caplostatin, angioextravasates along with them at sites of increased permeability statin, or saline. Data are expressed as mean ± SE. (Miles and Miles, 1952) . VPF/VEGF-induced extravasation of Evans blue dye was strikingly inhibited (by~70%) in mice treated for at least 24 hr with either TNP-470 or caplostatin (Figures 1A and 1B) . Angiostatin treatment for 5 days also in-51%, respectively ( Figure 1C ). Of interest, TNP-470 and caphibited the vascular permeabilizing effects of VPF/VEGF but to lostatin also blocked the low-level permeability induced by ina lesser extent (40%). In contrast, Herceptin and thalidomide, tradermal injections of PBS ( Figure 1C ). These results indicate angiogenesis inhibitors that act indirectly on EC (Kerbel and that angiogenesis inhibitors inhibit vascular permeability in-Folkman, 2002), did not affect VPF/VEGF-induced vascular duced by mediators that are thought to act by different mechapermeability ( Figures 1A and 1B) .
nisms and through different signaling pathways. To determine whether the antipermeabilizing effects of TNP-Comparisons of Miles assay results among different groups 470, caplostatin, and angiostatin were specific to VPF/VEGF, of animals are only valid if blood flow and volumes remain we tested their ability to inhibit the permeability-enhancing efequivalent. To rule out the possibility that TNP-470's action on fects of PAF and histamine. TNP-470 and caplostatin reduced permeability was attributable to an effect on blood flow, we Evans blue dye accumulation induced by PAF and histamine injected Evans blue dye i.v. into TNP-470-treated and unby 75% and 80%, respectively; treatment with angiostatin reduced PAF-and histamine-induced permeability by 37% and treated animals and collected skin samples 5 min later for dye extraction. The rationale was that at 5 min after i.v. injection of Evans blue there is very little extravasation of dye, so the vast majority is contained within the blood vasculature; thus, extracted dye provides a measure of blood volume and flow (H. Zeng and H.F.D., unpublished data). We found no significant difference between control and TNP-470-treated groups (0.004 ± 0.0001 and 0.005 ± 0.0002, respectively). If TNP-470 had affected skin blood flow, for example, by constricting microvessels, we would have expected a reduction in Evans blue dye accumulation.
TNP-470 decreases microvascular permeability in DTH reactions
DTH reactions are characterized by vascular hyperpermeability that is thought to be mediated by VPF/VEGF (Brown et al., 2000; Colvin and Dvorak, 1975) . We therefore determined whether TNP-470 would also inhibit the edema characteristic of these reactions. DTH reactions in C57Bl/6J mice sensitized with oxazolone and treated with TNP-470 exhibited significantly reduced erythema and ear swelling as compared with control mice at 24 and 48 hr (p < 0.01; Figures 2A and 2B ). No differences were found in the thickness of ears that were sensitized with the vehicle, but not challenged with oxazolone ( Figure 2A ). Histology confirmed the reduced swelling and showed that the inflammatory cell infiltrate was also reduced in TNP-470-treated mice ( Figure 2C ).
TNP-470 decreases pulmonary edema induced by IL-2
Patients with metastatic renal cell carcinoma and malignant melanoma sometimes respond to IL-2, but treatment with IL-2 is often limited by the development of systemic edema (Berthiaume et al., 1995) . We therefore sought to determine whether TNP-470 could prevent this adverse side effect using an IL-2induced pulmonary edema mouse model ( Figure 3 ). As expected, IL-2-treated mice developed edematous lungs with We next studied the effects of TNP-470 on tumor vessel permeability. We used six tumor cell lines whose expression of VPF/VEGF in vitro had been shown to differ widely and whose growth in vivo was inhibited to different extents (60%-95%) by secreted from the tumor and the ability of TNP-470 to inhibit TNP-470 ( Figure 4A ). Treatment with TNP-470 or caplostatin the permeability induced. Control saline-treated mice showed or with angiostatin in tumor-bearing mice inhibited Evans blue a dose-response correlation between increasing VPF/VEGF inextravasation, but to different extents in different tumors: jection and dye accumulation, up to saturation ( Figure 4C ). A2058 melanoma (p < 0.03 versus control), murine Lewis lung TNP-470-treated mice showed inhibition of permeability up to carcinoma (LLC) (p < 0.05), MCF-7 breast carcinoma (p < 0.04), 25 ng VPF/VEGF but, above that dose, TNP-470 lost its effec-MDA-MB-231 breast carcinoma (p < 0.05), and BXPC3 pancretiveness in inhibiting permeability and dye accumulation (Figatic adenocarcinoma (p < 0.04) by 40%-90% compared to ure 4C). control tumors treated with saline ( Figure 4B ). Interestingly, We also measured the levels of VPF/VEGF in U87 glioblasnone of the drugs inhibited Evans blue extravasation into U87 toma and A2058 melanoma tumor-bearing mice. VPF/VEGF glioblastomas ( Figure 4B ). A VPF/VEGF dose response was levels in A2058 melanoma tumors were measured at 20 pg/ 100 mg and in U87 glioblastomas at 3192 ± 762 pg/100 mg. used in a modified Miles assay to test the effect of VEGF A: Mice were pretreated with saline or TNP-470 for 3 days and then injected with IL-2 for 5 days. Lungs from euthanized mice were dissected and weighed. Data are expressed as mean ± SE. B: IL-2-induced pulmonary edema led to a massive thickening of the alveolar wall by extravasation of plasma proteins, generation of extracellular matrix, and cellular infiltration. Pretreatment with TNP-470 significantly reduced these effects.
Differences in vascular permeability could be affected by vessel number. Therefore, we determined whether TNP-470, caplostatin, or angiostatin had an effect on vessel density in mice implanted with the various tumor types. Following treatment with free or conjugated TNP-470 (for 3 days) or angiostatin (for 5 days), we found no significant difference in vessel density from control animals as determined by immunohistochemical staining for smooth muscle actin (SMA), proliferating cell nuclear antigen (PCNA), or CD31 staining in A2058 melanoma or U87 glioblastoma tumor models. CD31 staining of TNP-470, caplostatin, angiostatin, and untreated mice showed no difference in microvessel density in A2058 (76 ± 12, 90 ± A: VEGF levels in conditioned media of several cell lines. The growth of all tumors tested for permeability in B is known from the literature to be inhib-23, 65 ± 17, and 70 ± 14 microvessels/mm 2 ± standard error, ited by TNP-470, as shown in the right column of the table. References are respectively) or U87 glioblastoma (108 ± 24, 120 ± 13, 105 ± as follows: 1, Satchi-Fainaro et al. 2, McLeskey et al. (1996) ; 3, Ya-15, and 118 ± 30 microvessels/mm 2 ± standard error, respecmaoka et al. (1993) ; 4, R.S.-F., A.E. Birsner, and J.F., unpublished data; 5, tively). From this, we conclude that differences in permeability Takamiya et al. (1994) . B: Mice bearing LLC, A2058 melanoma, MCF-7 breast carcinoma, MDAcannot be attributed to changes in vessel number or vessel MB-231 breast carcinoma, BXPC3 pancreatic adenocarcinoma, or U87 glidensity. Thus, the effect of TNP-470 on VPF/VEGF-induced oblastoma were treated with saline (100%), TNP-470 (black columns), permeability occurs without any effect on vessel number or caplostatin (gray columns), or angiostatin (white columns; only LLC, A2058, density (vascular proliferation). and U87) for 3-5 days. Evans blue dye was injected, and after 10 min tumors were excised and weighed, and dye content per 100 mg tumor tissue was quantified at 620 nm. For each tumor, control group (saline) was de- Plasma proteins have been reported to extravasate from the C: C57Bl/6J mice were treated with TNP-470 (30 mg/kg/day s.c. for 3 days) or with saline and injected with Evans blue i.v. (10 min), followed by injecmicrovasculature by way of caveolae, fenestrae, and interention with VEGF intradermally at different concentrations. Skin punch biopdothelial cell gaps, and especially through vesiculo-vacuolar sies were collected, and extracted dye in formamide was read at 620 nm. organelles (VVOs), a recently described structure in the endo-Control saline-treated mice showed a dose-response correlation between thelium of normal venules and of some tumor vessels (reviewed increasing VEGF injection and dye accumulation, up to saturation. TNP-470-treated mice showed inhibition of permeability up to 25 ng, but above in Feng et al., 1996) . Using transmission electron microscopy, that dose, TNP-470 lost its effectiveness in inhibiting permeability and dye we found that TNP-470 had no effect on microvascular strucaccumulation.
TNP-470 does not affect the structure of vesiculo-
ture ( Figures 5A-5D ). VVOs were normal with respect to frequency and size, interendothelial cell junctions were normally closed, and fenestrae remained rare. Intravenously administered ferritin extravasated from VPF/VEGF-injected sites via vestigated the effects of TNP-470 and caplostatin on the VEGFR-2 signaling pathway in cultured EC. TNP-470 reduced VPF/VEGF-induced phosphorylation of VEGFR-2 in human dermal microvascular endothelial cells (HMVEC-d) ( Figure 6A ) and human umbilical vascular endothelial cells (HUVEC) ( Figure 6B ) and did so at doses as low as 50 pg/ml (data not shown).
TNP-470 inhibited growth factor-induced proliferation of HMVEC-d at concentrations as low as 1 pg/ml without causing cytotoxicity ( Figure 6C ); only at concentrations above 1 g/ml did TNP-470 become cytotoxic (below the basal cell proliferation in the absence of growth factors in the media). TNP-470 inhibited serum-induced proliferation (cytostatic effect) of U87 glioblastoma cells, but only at concentrations higher than 10 ng/ml ( Figure 6C) , and was only cytotoxic to tumor cells at concentrations higher than 100 g/ml. Thus, TNP-470 inhibited VPF/VEGF-induced EC proliferation at concentrations four orders of magnitude below that required to inhibit tumor cell growth. This difference in sensitivity between tumor and endothelial cells has been extensively investigated previously with different cell lines (Milkowski and Weiss, 1999; Satchi-Fainaro et al., 2004) .
TNP-470 and caplostatin also inhibited downstream signaling steps, including EC calcium influx ([Ca 2+ ] i ) ( Figure 6D ) necessary for vascular permeability and proliferation (D.M. and H.F.D., unpublished data), mitogen-activated protein kinase (MAPK) phosphorylation ( Figure 6G ), and RhoA activation (essential for VPF/VEGF-induced EC migration) ( Figure 7) .
Interestingly, TNP-470 and caplostatin also decreased Ca 2+ influx induced by histamine ( Figure 6E ) and by PAF ( Figure 6F ). with TNP-470 or caplostatin dramatically inhibited the chemotactic migration response to VPF/VEGF by 68% (p = 0.00045) and 87% (p = 0.000096), respectively ( Figure 7A ). In contrast, cells treated with HPMA copolymer alone (at 1 g/ml TNP-470-VVOs as expected, and treatment with TNP-470 reduced such equivalent concentration) migrated similarly to untreated conextravasation ( Figures 5F and 5H ). Small amounts of ferritin trol HMVEC-d. TNP-470 also inhibited basal migration of were also found in the VVOs of uninjected skin and in those of HMVEC-d cells in the absence of VPF/VEGF by 70% (p = skin injected with buffer ( Figure 5B ) in untreated animals, and 0.0023). this was reduced in mice treated with TNP-470 ( Figure 5D ).
The RhoA superfamily of small GTPase has been shown to Interendothelial cell junctions remained normally closed in all play a key role in cell proliferation, shape change, and migraconditions tested. We conclude, therefore, that the antipermetion (Aspenstrom, 1999) . RhoA and Rac1 are required for ability effect of TNP-470 is functional and not structural.
VEGFR-2-mediated HMVEC-d migration (Zeng et al., 2002) . The effect of TNP-470 on interendothelial junction proteins Therefore, we examined the possible role of RhoA in TNP-470's was tested. Cultured bovine capillary EC (BCE) treated with or inhibition of VPF/VEGF-mediated HMVEC-d migration. VPF/ without TNP-470 (1 ng/ml) exhibited no differences in expres-VEGF induced RhoA activation in HMVEC-d. TNP-470 signifision levels or distribution of occludin, claudin, ZO-1, β-catenin, cantly decreased VPF/VEGF-activated RhoA (Figure 7B ; densiand VE-cadherin (data not shown).
tometrical quantification shown on the figure) . These results suggest that RhoA inhibition by TNP-470, at least in part, leads TNP-470 inhibits VPF/VEGF-induced VEGFR-2 to the inhibition of VPF/VEGF-induced migration of HMVEC-d. phosphorylation, EC proliferation, Ca 2+ influx,
We also tested the effect of TNP-470 on PAF-induced (Figure and MAPK phosphorylation 7C) and histamine-induced ( Figure 7D ) RhoA activation, and VPF/VEGF is thought to achieve its multiple effects on vascular endothelium primarily by activating VEGFR-2. We therefore in-these were inhibited by TNP-470 and caplostatin as well. To determine whether VPF/VEGF-induced permeability was been paid to antiangiogenesis as an approach to tumor thermediated by the RhoA pathway, we used Y27632, a pharmacoapy. Tumors induce their new blood vessels by secreting angilogical inhibitor of Rock, a downstream target of RhoA (Breslin ogenic cytokines, of which VPF/VEGF is arguably the most imand Yuan, 2004) . Rock is a kinase that has been implicated in portant. Some antiangiogenic agents have well-defined the formation of cell-cell junctions. Pretreatment of SCID mice targets, such as antibodies against VEGF or kinase inhibitors with Y27632 inhibited VPF/VEGF-induced and Escherichia coli directed against VEGF receptors (Kerbel and Folkman, 2002) . cytotoxic necrotizing factor-1 (CNF-1)-induced Evans blue-However, little is known about the mechanism of action of albumin extravasation ( Figure 7E ). Activation of RhoA with other angiogenesis inhibitors, including TNP-470, caplostatin, CNF-1 (Hopkins et al., 2003) was sufficient to promote extravaand angiostatin, that act directly on vascular endothelium. The sation, because CNF-1 induced vessel leakage in the Miles present study was designed to determine whether these inhibiassay when injected intradermally ( Figures 7E and 7F) . This retors affected steps in the angiogenic cascade other than EC sponse was inhibited by Y27632; thus, RhoA pathway approliferation and to begin to define their molecular targets. We peared to be a key mediator of VPF/VEGF-induced leakage.
report here that TNP-470, caplostatin, and angiostatin act, at Pretreatment of SCID mice with TNP-470 also inhibited least in part, by inhibiting vascular permeability and EC migra-CNF-1-induced Evans blue-albumin extravasation (Figures 7E tion, both intrinsic properties of pathological angiogenesis. We and 7F). These results suggest that systemic in vivo inhibition also report initial studies that identify steps in the VPF/VEGF of RhoA causes inhibition of VPF/VEGF-induced vessel leakisignaling cascade that are affected by these agents. ness and that TNP-470 inhibits vessel permeability through in-Angiogenesis is a complex process that involves EC division, hibition of RhoA activation. migration, acquisition of pericytes, and other organizational steps, not all of which have been defined. In addition, all forms Discussion of pathological angiogenesis thus far identified are characterized by vascular hyperpermeability, a state thought to result Tumor growth beyond a minimal size requires the generation of new blood vessels, and for this reason recent attention has from the expression of VPF/VEGF (Carmeliet and Collen, 2000; Matsumoto and Claesson-Welsh, 2001) . Whether in tumors, inflammation, or wound healing, vascular hyperpermeability results in edema, clotting, and deposition of an extravascular fibrin gel that provides a provisional matrix that favors angiogenesis and mature stroma generation. Vascular hyperpermeability also contributes to morbidity caused by inducing fluid accumulation in body cavities (e.g., pleural and peritoneal cavities) and in the brain, where edema can become a lifethreatening complication (Ohnishi et al., 1990) . Recently, prevention of microvascular permeability by endothelial nitric oxide synthase (eNOS) inhibition (see below) has been successfully exploited as an approach to tumor therapy (Gratton et al., 2003) . Given this background, we set out to determine whether the potent angiogenesis inhibitors TNP-470, caplostatin, and angiostatin had an effect on vascular permeability in tumors and other examples of pathological angiogenesis. All six of the tumors studied exhibited increased permeability, and we demonstrated that TNP-470, caplostatin, and angiostatin effectively inhibited the permeability response in five tumors. The lone exception was the U87 glioblastoma, a tumor that secretes unusually large amounts of VPF/VEGF. This finding might be explained by the dose-response data that show a threshold above which TNP-470 is not able to inhibit VPF/VEGF-induced permeability, at least under the conditions of our experiments. Nonetheless, TNP-470 did inhibit the growth of the U87 tumor, indicating that factors other than its antipermeability action contribute to TNP-470's effectiveness in preventing tumor growth. TNP-470 was also effective in inhibiting the vascular permeability characteristic of delayed hypersensitivity reactions, which, like that of tumors, is thought to result from VPF/ VEGF expression.
Other experiments were performed to determine whether the action of TNP-470 and angiostatin was specific for VPF/VEGFinduced vascular permeability. We demonstrated that treatment of mice with TNP-470 for as little as 24 hr suppressed not only the permeability response to VPF/VEGF but also that to PAF and histamine. We also demonstrated that animals treated with TNP-470 were protected from the pulmonary edema induced by IL-2. Taken together, these data indicate that TNP-470, caplostatin, and angiostatin inhibit the vascular permeability responses induced by a variety of agonists that have been thought to act in different ways and by different signaling pathways. Endostatin (M. Nomi, G. Schuch, N. Kilic, L. Oliveira-Ferrer, R.S.-F., J. Weil, D.K.H., A. Atala, J.F., S. Soker, and S. Ergun, personal communication) and endostatin peptides (Tjin Tham Sjin et al., 2005) also inhibit vascular permeability. It is possible, therefore, that these agents, and particularly TNP-470 in its nontoxic polymeric form, will be of therapeutic value not only in tumors but also in other circumstances where vascular permeability is a problem, e.g., inflam- of EC structure showed that VVOs were found to be normal in number and extent, interendothelial cell junctions appeared to be normal, and fenestrae were not detectably increased in TNP-470-treated animals. These data indicate that TNP-470 affects EC function but not structure. Consistent with these results, we found no changes in junctional proteins of cultured EC that were treated with TNP-470. In addition to inhibiting vascular permeability and EC proliferation, TNP-470 also inhibited VPF/VEGF-induced EC migration. Recent work has done much to elucidate the signaling steps by which VPF/VEGF mediates its several effects, and we therefore sought to define the signaling events that were inhibited by TNP-470. We found that TNP-470 inhibited VEGFR-2 phosphorylation as well as such downstream signaling steps (Hall, 1998; Ingber, 2002) and has an important role in vascular leakage by opening of interendothelial junctions, endothelial fenestration, generation of transendothelial gaps, and transcytotic vesicles both EC proliferation and migration. Further, it has been sugincluding VVO. Pretreatment with TNP-470 decreases the leakage via gested that RhoA activation triggers Ca 2+ entry via intracellular transcytotic vesicles. TNP-470 inhibited VEGFR-2 phosphorylation, [Ca 2+ ] i , store depletion, a precursor step to endothelial permeability and RhoA activation in vascular endothelium. This model suggests that (Mehta et al., 2003) . It has long been known that VPF/VEGF TNP-470 transforms angiogenic and hyperpermeable vessels to a less leaky morphologic phenotype.
stimulates transient accumulation of cytoplasmic calcium in cultured EC (Brock et al., 1991) . The increases in endothelial cytosolic Ca 2+ induced by VPF/VEGF, and also by PAF and histamine, likely activate calcium/calmodulin-dependent en-Cell culture zymes such as eNOS. It has been previously shown that TNP-Tumor cells (A2058 human melanoma, U87 human glioblastoma, BXPC3, 470 inhibits nitric oxide production (Mauriz et al., 2003) , and LLC, MCF-7, MDA-MB-231) were obtained from the American Type Culture nitric oxide has been implicated in VPF/VEGF-driven vascular Collection (Manassas, VA). Cells were cultured as previously described permeability (Fukumura et al., 2001) . Activation of eNOS by (Satchi-Fainaro et al., 2004) . BCE cells were isolated and maintained as described (Folkman et al., 1979) . HMVEC-d and HUVEC were obtained from VPF/VEGF involves several pathways, including Akt/PKB, Cambrex (Walkersville, MD) and grown according to the manufacturer's procalcium/calmodulin, and protein kinase C (Aoyagi et al., 2003;  tocol in EGM-2 MV medium or EGM, respectively, supplemented with bullet Aramoto et al., 2004) . Taking all of these facts together, we kits (Cambrex). have proposed in Figure 8 a model by which TNP-470 may act as an antipermeability factor.
Mice
C57Bl/6J mice were purchased from Jackson Laboratories (USA), and CB-Experimental procedures 17 SCID mice were purchased from Massachusetts General Hospital (USA). All animal procedures were performed in compliance with Boston Children's Materials
Hospital guidelines and protocols approved by the Institutional Animal Care TNP-470 was kindly provided by Takeda Chemical Industries Ltd. (Japan). and Use Committee. HPMA copolymer precursor was from Polymer Laboratories (UK). Caplostatin was synthesized as previously described (Satchi-Fainaro et al., 2004) .
Miles vascular permeability assay VEGF 165 was a gift from the NIH (Bethesda, CA). Bovine serum albumin SCID mice were injected subcutaneously (s.c.) with TNP-470 or caplostatin (BSA), dimethylformamide (DMF), formamide, Evans blue, histamine, and (30 mg/kg TNP-470-equivalent concentration) for 3 days, with Y27632 (50 oxazolone (4-Ethoxymethylene-2-phenyloxazolone) were from Sigma (St. nM s.c.) for 11 days, with angiostatin (200 mg/kg/day s.c.) for 5 days, or Louis, MO). PAF was from Biomol (Plymouth Meeting, PA), Vivacell 70 ml with saline (250 l s.c.) for 5 days (n = 12 mice/group) before the Miles dialysis system (10 kDa MW cutoff PES) was from VivaScience (USA).
assay was performed (Claffey et al., 1996; Miles and Miles, 1952 ; Streit et Isoflurane was purchased from Baxter Healthcare Corporation (USA). Matrial., 2000) . Briefly, Evans blue dye (100 l of a 1% solution in 0.9% NaCl) gel was from Becton Dickinson (USA), Avertin was from Fisher (USA), and was injected intravenously (i.v.) into mice. After 10 min, 50 l of human thalidomide was from Celgene (USA). Human and mouse VPF/VEGF quan-VEGF 165 (1 ng/l), PAF (100 M), CNF-1 (100 ng), histamine (1.2 g/ml), or tikine ELISA kits were purchased from R&D Systems Inc. (Minneapolis, MN) .
PBS was injected intradermally into the preshaved back skin. After 20 min, Angiostatin was from EntreMed (USA), anti-Erb B-2 antibody (Herceptin) the animals were euthanized, and an area of skin that included the entire was from Genentech (USA), and IL-2 was a gift from Dr. Steven A. Roseninjection site was removed. Evans blue dye was extracted from the skin by berg (NIH). Rabbit polyclonal antibody against RhoA, anti-Flk-1 mouse moincubation with formamide for 5 days at room temperature, and the absornoclonal, and an antibody against phosphorylated tyrosine (pTyr) mouse bance of extracted dye was measured at 620 nm. In addition, in order to monoclonal were purchased from Santa Cruz Biotechnology (Santa Cruz, test the effect of TNP-470 on blood volume and flow we measured dye CA). Anti-Phospho-p44/42 MAPK mouse monoclonal antibody and antiaccumulation in the uninjected flank skin of mice treated as above with p44/42 MAPK rabbit polyclonal antibody were from Cell Signaling Technol-TNP-470 or saline. Five minutes later, we performed punch biopsies of flank ogy, Inc. Y27632 was from Calbiochem (San Diego, CA). His-CNF1 plasmid skin from both sets of mice and extracted these with formamide as above.
The unpaired Student's t test was used for statistical analysis. was a gift from Melody Mills (Uniformed Services University of Health Sciences, MD) and was expressed in Escherichia coli; recombinant CNF-1 was purified with the QIAGEN kit. Glutathione-S-transferase (GST)-Rhotekin Rho Tissue processing for electron microscopy binding domain (TRBD) fusion protein was provided by Dr. Martin Schwartz SCID mice were treated for 3 days with TNP-470 or saline as above, following which anionic ferritin was injected as tracer i.v.; 50 l of human VEGF 165 (Scripps Institute) (Ren et al., 1999) .
(1 ng/l) or 50 l of PBS was then injected i.d. into preshaved flank skin.
ELISA assays for VPF/VEGF Blood drawn from tumor-bearing mice was centrifuged, and plasma was After 15 min, animals were euthanized. Skin test and control sites were collected. Solid tumors were homogenized and resuspended in lysis buffer. excised and fixed by immersion and processed for electron microscopy as
In addition, tumor cells were plated at 500,000 cells per well (six-well previously described Feng et al., 1996) .
plates), and conditioned medium from cells was collected 48 hr later. Levels of VPF/VEGF in plasma, tumors, and culture supernatants were determined Endothelial junctional proteins in duplicate samples by ELISA (R&D Systems, MN). BCE were cultured on glass coverslips in a 24-well plate (200,000 cells/ well) in Dulbecco's modified Eagle's medium (DMEM) + 10% bovine calf Cell proliferation assay serum (BCS) + 3 ng/ml bFGF in the presence or absence of TNP-470 (1 ng/ HMVEC-d cells were plated at 15,000 cells/ml onto gelatinized 24-well culml) for 3 days. Thereafter, PAF (100 M) or VEGF (50 ng/ml) was added for ture plates in EBM-2 supplemented with 5% fetal bovine serum (FBS) and 20 min, and the cells were fixed in paraformaldehyde 4% for 10 min and in incubated for 24 hr (37°C; 5% CO 2 ). Medium was replaced with complete methanol for 5 min at room temperature. Fixed cells were incubated overmedia (serum and growth factors; EGM-2 MV). U87 glioblastoma cells were night with polyclonal antibodies to occludin, claudin, ZO-1, or VE-cadherin plated at 5000 cells/ml in DMEM supplemented with 10% FBS and incuor a monoclonal antibody to β-catenin (Zymed Laboratories, South San bated for 24 hr (37°C; 5% CO 2 ). Medium was replaced with DMEM and Francisco, CA). The staining was subsequently developed with FITC-conju-10% FBS. Both cell types were challenged with free or conjugated TNPgated secondary antibodies and photographed using a fluorescent micro-470 (0.01 pg/ml to 1 mg/ml TNP-470-equivalent concentration). Control scope. cells were grown with or without growth factors. Both cell types were incubated for 72 hr, followed by trypsinization and resuspension in Hematall DTH reactions (Fisher Scientific, Pittsburgh, PA) , and counted in a Coulter counter. DTH reactions were induced in the flank skin of 8-week-old C57Bl/6J male mice (n = 5) as previously described (Dvorak et al., 1984) . Mice were sensi-Cell migration assay tized by topical application of 2% oxazolone solution in vehicle (acetone:ol-Cell migration was performed as previously described (Short et al., 2005) ive oil, 4:1 vol/vol), to the shaved abdomen (50 l) and to each paw (5 l).
with the following modifications: suspended HMVEC-d were treated with Mice were treated with TNP-470 (30 mg/kg s.c.) for 3 days beginning on free or conjugated TNP-470 at equivalent concentrations of 1 ng/ml, and day 2, and at 5 days the right ears were challenged by topical application cells were added to the upper chamber of the transwell for a 2 hr incubation of 10 l of a 1% oxazolone solution; the left ears were treated with vehicle prior to migration to VEGF. alone. Ear thickness was then measured daily for 7 days as a measure of inflammation intensity (Gad et al., 1986) . Statistical analysis was performed VEGFR-2 phosphorylation Serum-starved (0.1% FBS in EBM-2 media for 24 hr) HMVEC-d or HUVEC using the unpaired Student's t test. Some mice from each experimental were treated with 5 ng/ml TNP-470 and caplostatin at 37°C for 2 hr and group were euthanized 24 hr after oxazolone challenge (n = 5 per group).
then stimulated with 10 ng/ml of VEGF for 5 min. Stimulation was stopped One half of each ear was fixed in 10% formalin and processed for H&Eby adding cold PBS. Cells were lysed with cold precipitation buffer (20 mM stained paraffin sections. The other half was embedded in OCT compound Tris-HCl [pH 7.5], 0.15 M NaCl, 1% Triton X-100, 1 mM PMSF, 1 mM (Sakura Finetek, Torrance, CA) and snap frozen in liquid nitrogen for immu-Na 3 VO 4 , 1 mM EGTA, 1 g/ml leupeptin, 0.5% aprotinin, and 2 g/ml pepnohistochemical staining of 5 m cryostat sections using a Vecstatin avidinstatin A). Lysate protein (500 g) was incubated with 1 g of antibody biotin detection system (Vector Labs, Burlingame, CA) with rat monoclonal against VEGFR-2 for 2 hr, then with 50 µl of protein A-conjugated agarose antibodies against mouse CD31 (dilution 1:250; Pharmingen, San Diego, CA). beads at 4°C for 3-4 hr. After the beads were washed with precipitation buffer, immunoprecipitates were resuspended in 2× SDS sample buffer for
IL-2-associated pulmonary edema
Western blot analysis with an antibody against phosphorylated tyrosine C57Bl/6J male mice were injected with TNP-470 (30 mg/kg daily) or saline (pTyr). s.c. for 3 days. Then, mice were injected with IL-2 (1.2 × 10 6 units/100 l) or saline intraperitoneally (i.p.) three times a day for 5 days. At termination, RhoA activation assay mice were euthanized, and lungs were dissected, weighed, fixed, and pro-pGST-TRBD bacteria were grown and induced with isopropyl-thiogalactocessed for H&E staining. side. The bacterial suspensions were divided into 50 ml aliquots and then harvested and frozen at −80°C. To prepare the GST-TRBD beads, each Tumor vascular permeability aliquot of frozen bacteria was resuspended in 2 ml of cold PBS, and then Female SCID mice (~8 weeks,~20 g) were inoculated s.c. with 5 × 10 6 20 µl of 1 M dithiothreitol (DTT), 20 µl of 0.2 M PMSF, and 40 µl of 50 mg/ viable U87 glioblastoma, A2058 human melanoma, or BXPC3 pancreas adml lysozyme were added. The sample was incubated on ice for 30 min. enocarcinoma cells. Female nu/nu mice were inoculated with 1 × 10 6 MCF-7
Next, 225 µl of 10% Triton X-100, 22.5 µl of 1 M MgCl 2 , and 22.5 µl of 2000 KU/ml DNase were added, and the sample was incubated on ice for another or MDA-MB-231 breast carcinoma cells in the mammary fat pad. C57Bl/6J 30 min. The supernatant was collected and incubated with 100 µl glutathiwere inoculated s.c. with 5 × 10 6 LLC cells. When tumors reached a volume one-coupled Sepharose 4B beads (Pharmacia Biotech) at 4°C for 45 min. of approximately 100 mm 3 , mice were injected s.c. with free TNP-470 (as The beads were then washed with bead-washing buffer (PBS with 10 mM above) or caplostatin (30 mg/kg TNP-470-equivalent concentration) for 3 DTT and 1% Triton X-100) and resuspended in the same buffer to give a days, angiostatin (200 mg/kg s.c.) for 5 days, or saline (250 l s.c.) for 5 50% bead slurry. days (n = 10). Evans blue dye was then injected i.v., and dye was extracted HMVEC-d cells serum-starved for 24 hr were treated with 5 ng/ml TNPand assessed as above. Also, VPF/VEGF levels were measured in plasma 470 at 37°C for 2 hr and then stimulated with 10 ng/ml of VEGF, PAF (10 and in tumors (n = 5 from each group). Tumors (n = 5 per group) were nM), or histamine (100 mM) for 5 min. Stimulation was stopped by adding dissected, weighed, and bisected. Half of each tumor was placed in formacold PBS. Cells were lysed with lysis buffer (150 mM NaCl, 0.8 mM MgCl 2 , lin, and half was analyzed for VPF/VEGF protein by ELISA (see below). For-5 mM EGTA, 1% IGEPAL, 50 mM HEPES [pH 7.5], 1 mM PMSF, 10 µg/ malin-fixed tumors were processed for H&E sections as above and for ml leupeptin, and 10 µg/ml aprotinin). The supernatant was isolated and CD31, SMA, and PCNA staining according to the manufacturer's instrucincubated with 50 µl of GST-TRBD beads at 4°C for 45 min. Protein bound tions.
to beads was washed with AP wash buffer (50 mM Tris-HCl [pH 7.2], 1% To determine the ability of TNP-470 to inhibit the permeability response Triton X-100, 150 mM NaCl, 10 mM MgCl 2 , 1 mM PMSF, 10 µg/ml leupeptin, induced by increasing doses of VPF/VEGF, 8-week-old C57Bl/6J mice were and 10 µg/ml aprotinin) and analyzed by SDS-PAGE with an antibody treated with TNP-470 (30 mg/kg/day s.c. for 3 days) or with saline. Evans against RhoA (Santa Cruz Biotechnology, CA). blue (100 l; 1%) was injected i.v., and after 10 min VPF/VEGF was injected intradermally at increasing concentrations (from 2.5 × 10 −5 to 250 ng/ml).
Phosphorylation of MAPK Twenty minutes later, punch biopsies of flank skin from both sets of mice Serum-starved HMVEC-d were treated with 5 ng/ml TNP-470 at 37°C for 2 hr and then stimulated with 10 ng/ml of VEGF for 5 min. Stimulation was were taken and processed as above.
